Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Department of Endocrinology, Wuxi Hospital of Traditional Chinese Medicine, Wuxi, China.
Front Endocrinol (Lausanne). 2021 Dec 24;12:813067. doi: 10.3389/fendo.2021.813067. eCollection 2021.
To explore the chronic effects of metformin on testosterone levels in men with type 2 diabetes mellitus (T2DM).
This is a secondary analysis of a real-world study evaluating the efficacy and safety of premixed insulin treatment in patients with T2DM 3-month intermittent flash glucose monitoring. Male patients aged 18-60 who were using metformin during the 3-month study period were included as the metformin group. The control group included males without metformin therapy by propensity score matching analysis with age as a covariate. Testosterone levels were measured at baseline and after 3-month treatment.
After 3-month treatment, the control group had higher levels of total testosterone, free and bioavailable testosterone than those at baseline (P<0.05). Compared with the control group, the change of total (-0.82 ± 0.59 vs. 0.99 ± 0.59 nmol/L) and bioavailable (-0.13 ± 0.16 vs. 0.36 ± 0.16 nmol/L) testosterone levels in the metformin group significantly decreased (P=0.036 and 0.029, respectively). In Glycated Albumin (GA) improved subgroup, the TT, FT, and Bio-T levels in the control subgroup were higher than their baseline levels (P < 0.05). Compared with the metformin subgroup, TT level in the control subgroup also increased significantly (P=0.044). In GA unimproved subgroup, the change of TT level in the metformin subgroup was significantly lower than that in the control subgroup (P=0.040).
In men with T2DM, 3-month metformin therapy can reduce testosterone levels, and counteract the testosterone elevation that accompanied with the improvement of blood glucose.
https://www.clinicaltrials.gov/ct2/show/NCT04847219?term=04847219&draw=2&rank=1.
探讨二甲双胍对 2 型糖尿病（T2DM）男性患者睾酮水平的慢性影响。
这是一项真实世界研究的二次分析，该研究评估了在 3 个月间歇性闪光血糖监测期间，使用预混胰岛素治疗 T2DM 患者的疗效和安全性。将在 3 个月研究期间使用二甲双胍的年龄在 18-60 岁的男性患者纳入二甲双胍组。对照组为采用倾向评分匹配分析，以年龄为协变量，无二甲双胍治疗的男性。在基线和 3 个月治疗后测量睾酮水平。
治疗 3 个月后，对照组的总睾酮、游离睾酮和生物可利用睾酮水平均高于基线（P<0.05）。与对照组相比，二甲双胍组总睾酮（-0.82±0.59 对 0.99±0.59 nmol/L）和生物可利用睾酮（-0.13±0.16 对 0.36±0.16 nmol/L）水平的变化明显降低（P=0.036 和 0.029）。在糖化白蛋白（GA）改善亚组中，对照组的 TT、FT 和 Bio-T 水平高于基线水平（P<0.05）。与二甲双胍组相比，对照组的 TT 水平也明显升高（P=0.044）。在 GA 未改善亚组中，二甲双胍组的 TT 水平变化明显低于对照组（P=0.040）。
在 T2DM 男性中，3 个月的二甲双胍治疗可降低睾酮水平，并抵消血糖改善伴随的睾酮升高。
https://www.clinicaltrials.gov/ct2/show/NCT04847219?term=04847219&draw=2&rank=1.
